Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) EBT Margin (2016 - 2025)

Amphastar Pharmaceuticals has reported EBT Margin over the past 13 years, most recently at 20.34% for Q4 2025.

  • Quarterly results put EBT Margin at 20.34% for Q4 2025, down 613.0% from a year ago — trailing twelve months through Dec 2025 was 17.91% (down 875.0% YoY), and the annual figure for FY2025 was 17.91%, down 875.0%.
  • EBT Margin for Q4 2025 was 20.34% at Amphastar Pharmaceuticals, up from 11.21% in the prior quarter.
  • Over the last five years, EBT Margin for AMPH hit a ceiling of 35.25% in Q3 2023 and a floor of 78.93% in Q4 2023.
  • Median EBT Margin over the past 5 years was 22.49% (2021), compared with a mean of 12.74%.
  • Biggest five-year swings in EBT Margin: crashed -8612bps in 2022 and later soared 10540bps in 2024.
  • Amphastar Pharmaceuticals' EBT Margin stood at 22.47% in 2021, then plummeted by -383bps to 63.65% in 2022, then dropped by -24bps to 78.93% in 2023, then skyrocketed by 134bps to 26.47% in 2024, then dropped by -23bps to 20.34% in 2025.
  • The last three reported values for EBT Margin were 20.34% (Q4 2025), 11.21% (Q3 2025), and 22.55% (Q2 2025) per Business Quant data.